Indolent T-Cell Non-Hodgkin Lymphoma — Trials

Indolent T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

134 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 33
Recruiting: 16
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: City of Hope Medical Center
Termination share: 46.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (31)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03278782	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin	active not recruiting	Phase 1 / Phase 2	39	M.D. Anderson Cancer CenterOTHER	1	Sep 30, 2026	clinicaltrials
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	active not recruiting	Phase 2	68	National Cancer Institute (NCI)NIH	1	Aug 13, 2026	clinicaltrials